tickdelta
tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

RMDResMed

Health care · Medical Instruments · NYSE, OTC
RMD quote by TradingView
Compare with peers → Embed
FY2026 at a glance

Sales up 9.9%, free cash flow down to $1.6B

XBRL, from each 10-K
RevenueStatements ↓
$5.7B
from $5.1B in FY2025
FY2017FY2026
Net incomeStatements ↓
$1.5B
from $1.4B in FY2025
FY2017FY2026
Free cash flowStatements ↓
$1.6B
from $1.7B in FY2025
FY2017FY2026
EPS (diluted)Statements ↓
$10.43
from $9.51 in FY2025
FY2017FY2026
Operating marginStatements ↓
33.4%
from 32.7% in FY2025
FY2017FY2026
Total debtStatements ↓
$659.4M
from $668.3M in FY2025
FY2017FY2026
Price and key numbers

The latest figures

All key numbers (42, from the latest 10-K and 10-Q) From EDGAR
EPS (ttm)10.98Sales (ttm)5.7BNet income (ttm)1.6BSales growth+9.9%EPS growth+9.7%Sales Q/Q+5.9%
Free cash flow1.6BGross margin61.1%Oper. margin33.0%Net margin27.8%FCF margin28.1%ROE26.8%
ROA19.4%R&D / sales6.7%Dividend2.40Debt/Eq0.07Curr. ratio2.65Cash1.0B
Op. cash flow (ttm)1.8BEBITDA2.1BEBITDA margin36.9%Net debt-601.1MQuick ratio1.94Interest cover69.73
ROIC23.6%Payout ratio23.0%Tax rate20.6%Stock pay / sales1.8%Shares out.140.7MShares Y/Y-0.9%
Book / share42.29Cash / share7.19Sales / share40.76Asset turnover0.70Inventory turns2.33Days sales out.67
Sales 3Y CAGR+10.2%Sales 5Y CAGR+12.1%EPS 3Y CAGR+19.6%EPS 5Y CAGR+26.3%Employees11,370Sales / employee504K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

RMD against Health care peers

Ten years, side by side → · All 60 →
GrowthProfitBalanceCleanInsiders
RMDPeer median

Each side 0 to 100, ranked against every company we cover: relative position on reported figures, not a buy score. How

Every dot is one of the 60 companies, the better end on the right. Hover a dot for the company.

Sales growth
+9.9%20th of 60 · median +7.1%
Net margin
27.8%5th of 60 · median 9.6%
Return on equity
26.8%10th of 54 · median 13.1%
Free cash flow margin
28.1%4th of 56 · median 15.5%
Debt / equity (less is better)
0.074th of 49 · median 0.66
RMD and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthGross marginNet marginROEFCF marginDebt / equity
RMD ResMed$5.7B +9.9%61.1%27.8%26.8%28.1%0.07
EW Edwards Lifesciences$6.7B +11.5%78.0%15.3%9.4%21.3%0.06
STE Steris$6.2B +8.7%44.6%13.4%11.4%15.2%0.26
INCY Incyte$6.0B +21.2%92.7%6.7%7.1%--
DXCM Dexcom$5.1B +15.6%63.4%19.4%39.1%21.5%-
IDXX Idexx Laboratories$4.7B +10.4%62.7%25.4%63.2%28.0%0.20
Where each dollar goes

From $3.6B of sales to $779.4M of profit

FY2022, from the 10-K income statement
Revenue to Gross profit: $2.0BRevenue to Cost of revenue: $1.6BGross profit to Operating profit: $1.0BGross profit to Operating expenses: $1.0BOperating profit to Net profit: $779.4MOperating profit to Tax & other: $220.8MOperating expenses to R&D: $253.6MOperating expenses to Sales, admin & other: $770.5M Revenue: $3.6B Revenue$3.6B +12% Y/Y Gross profit: $2.0B · 57% margin Gross profit$2.0B57% margin +10% Y/Y Cost of revenue: $1.6B · 43% of revenue Cost of revenue$1.6B43% of revenue Operating profit: $1.0B · 28% margin Operating profit$1.0B28% margin +11% Y/Y Operating expenses: $1.0B · 29% of revenue Operating expenses$1.0B29% of revenue Net profit: $779.4M · 22% margin Net profit$779.4M22% margin +64% Y/Y Tax & other: $220.8M · 6% of revenue Tax & other$220.8M6% of revenue R&D: $253.6M · 7% of revenue R&D$253.6M7% of revenue Sales, admin & other: $770.5M · 22% of revenue Sales, admin & other$770.5M22% of revenue

Swipe sideways for the whole flow →

From $4.2B of sales to $897.6M of profit

FY2023, from the 10-K income statement and revenue by product
Sleep and Breathing Health to Revenue: $3.7BResidential Care Software to Revenue: $498.0MRevenue to Gross profit: $2.4BRevenue to Cost of revenue: $1.9BGross profit to Operating profit: $1.1BGross profit to Operating expenses: $1.2BOperating profit to Net profit: $897.6MOperating profit to Tax & other: $234.3MOperating expenses to R&D: $287.6MOperating expenses to Sales, admin & other: $936.1M Sleep and Breathing Health: $3.7B · 88% Sleep and Breathing Hea…$3.7B88% Residential Care Software: $498.0M · 12% Residential Care Softwa…$498.0M12% Revenue: $4.2B Revenue$4.2B +18% Y/Y Gross profit: $2.4B · 56% margin Gross profit$2.4B56% margin +16% Y/Y Cost of revenue: $1.9B · 44% of revenue Cost of revenue$1.9B44% of revenue Operating profit: $1.1B · 27% margin Operating profit$1.1B27% margin +13% Y/Y Operating expenses: $1.2B · 29% of revenue Operating expenses$1.2B29% of revenue Net profit: $897.6M · 21% margin Net profit$897.6M21% margin +15% Y/Y Tax & other: $234.3M · 6% of revenue Tax & other$234.3M6% of revenue R&D: $287.6M · 7% of revenue R&D$287.6M7% of revenue Sales, admin & other: $936.1M · 22% of revenue Sales, admin & other$936.1M22% of revenue

Swipe sideways for the whole flow →

From $4.7B of sales to $1.0B of profit

FY2024, from the 10-K income statement and revenue by product
Sleep and Breathing Health to Revenue: $4.1BResidential Care Software to Revenue: $584.1MRevenue to Gross profit: $2.7BRevenue to Cost of revenue: $2.0BGross profit to Operating profit: $1.3BGross profit to Operating expenses: $1.3BOperating profit to Net profit: $1.0BOperating profit to Tax & other: $298.9MOperating expenses to R&D: $307.5MOperating expenses to Sales, admin & other: $1.0B Sleep and Breathing Health: $4.1B · 88% Sleep and Breathing Hea…$4.1B88% Residential Care Software: $584.1M · 12% Residential Care Softwa…$584.1M12% Revenue: $4.7B Revenue$4.7B +11% Y/Y Gross profit: $2.7B · 57% margin Gross profit$2.7B57% margin +13% Y/Y Cost of revenue: $2.0B · 43% of revenue Cost of revenue$2.0B43% of revenue Operating profit: $1.3B · 28% margin Operating profit$1.3B28% margin +17% Y/Y Operating expenses: $1.3B · 29% of revenue Operating expenses$1.3B29% of revenue Net profit: $1.0B · 22% margin Net profit$1.0B22% margin +14% Y/Y Tax & other: $298.9M · 6% of revenue Tax & other$298.9M6% of revenue R&D: $307.5M · 7% of revenue R&D$307.5M7% of revenue Sales, admin & other: $1.0B · 22% of revenue Sales, admin & other$1.0B22% of revenue

Swipe sideways for the whole flow →

From $5.1B of sales to $1.4B of profit

FY2025, from the 10-K income statement and revenue by product
Sleep and Breathing Health to Revenue: $4.5BResidential Care Software to Revenue: $641.4MRevenue to Gross profit: $3.1BRevenue to Cost of revenue: $2.1BGross profit to Operating profit: $1.7BGross profit to Operating expenses: $1.4BOperating profit to Net profit: $1.4BOperating profit to Tax & other: $284.6MOperating expenses to R&D: $331.3MOperating expenses to Sales, admin & other: $1.0B Sleep and Breathing Health: $4.5B · 88% Sleep and Breathing Hea…$4.5B88% Residential Care Software: $641.4M · 12% Residential Care Softwa…$641.4M12% Revenue: $5.1B Revenue$5.1B +10% Y/Y Gross profit: $3.1B · 59% margin Gross profit$3.1B59% margin +15% Y/Y Cost of revenue: $2.1B · 41% of revenue Cost of revenue$2.1B41% of revenue Operating profit: $1.7B · 33% margin Operating profit$1.7B33% margin +28% Y/Y Operating expenses: $1.4B · 27% of revenue Operating expenses$1.4B27% of revenue Net profit: $1.4B · 27% margin Net profit$1.4B27% margin +37% Y/Y Tax & other: $284.6M · 6% of revenue Tax & other$284.6M6% of revenue R&D: $331.3M · 6% of revenue R&D$331.3M6% of revenue Sales, admin & other: $1.0B · 20% of revenue Sales, admin & other$1.0B20% of revenue

Swipe sideways for the whole flow →

From $5.7B of sales to $1.5B of profit

FY2026, from the 10-K income statement and revenue by product
Sleep and Breathing Health to Revenue: $5.0BResidential Care Software to Revenue: $675.8MRevenue to Gross profit: $3.5BRevenue to Cost of revenue: $2.2BGross profit to Operating profit: $1.9BGross profit to Operating expenses: $1.6BOperating profit to Net profit: $1.5BOperating profit to Tax & other: $363.4MOperating expenses to R&D: $378.3MOperating expenses to Sales, admin & other: $1.2B Sleep and Breathing Health: $5.0B · 88% Sleep and Breathing Hea…$5.0B88% Residential Care Software: $675.8M · 12% Residential Care Softwa…$675.8M12% Revenue: $5.7B Revenue$5.7B +10% Y/Y Gross profit: $3.5B · 61% margin Gross profit$3.5B61% margin +13% Y/Y Cost of revenue: $2.2B · 39% of revenue Cost of revenue$2.2B39% of revenue Operating profit: $1.9B · 33% margin Operating profit$1.9B33% margin +12% Y/Y Operating expenses: $1.6B · 28% of revenue Operating expenses$1.6B28% of revenue Net profit: $1.5B · 27% margin Net profit$1.5B27% margin +9% Y/Y Tax & other: $363.4M · 6% of revenue Tax & other$363.4M6% of revenue R&D: $378.3M · 7% of revenue R&D$378.3M7% of revenue Sales, admin & other: $1.2B · 21% of revenue Sales, admin & other$1.2B21% of revenue

Swipe sideways for the whole flow →

Where each $100 of sales went

FY2022
FY2023
FY2024
FY2025
FY2026
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax, less other income
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement →

Profitability

4 of 4
  • ✓
    Net margin above the peer median27.8% vs 9.6%
  • ✓
    Gross margin up over 5 years57.5% → 61.1%
  • ✓
    Return on equity above 15%26.8%
  • ✓
    A profit in every one of 10 years
Net margin, FY2017 to FY2026: 16.6% → 26.9%

Balance sheet

4 of 4
  • ✓
    Interest covered more than 5 timesOperating income is 69.7× interest expense
  • ✓
    Debt smaller than equityDebt / equity 0.07 on the latest balance sheet (peer median 0.66)
  • ✓
    Current assets cover current liabilitiesCurrent ratio 2.65
  • ✓
    More cash than debtNet cash $601.1M
Debt / equity at each year end, FY2017 to FY2026: 0.55 → 0.10
What the debt is made of ↓

Cash and shareholders

4 of 4
  • ✓
    Free cash flow positive in every one of 10 years$1.6B last year
  • ✓
    Share count down over 5 years−0.3%
  • ✓
    Dividend per share up over 5 years$1.56 → $2.40
  • ✓
    Cash from operations above net income$1.8B vs $1.5B
Free cash flow, FY2017 to FY2026: 351.8M → 1.6B

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Debt

$- of principal due

Repayment schedule →

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Revenue and net income, FY2017 to FY2026

Revenue 5.7B Net income 1.5B
FY2017 revenue 2.1B · Revenues, 0000943819-19-000017 FY2017 net income 342.3M · NetIncomeLoss, 0000943819-19-000017 2.1B FY2017 FY2018 revenue 2.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000943819-20-000013 FY2018 net income 315.6M · NetIncomeLoss, 0000943819-20-000013 2.3B FY2018 FY2019 revenue 2.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000943819-21-000017 FY2019 net income 404.6M · NetIncomeLoss, 0000943819-21-000017 2.6B FY2019 FY2020 revenue 3.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000943819-22-000010 FY2020 net income 621.7M · NetIncomeLoss, 0000943819-22-000010 3.0B FY2020 FY2021 revenue 3.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000943819-23-000011 FY2021 net income 474.5M · NetIncomeLoss, 0000943819-23-000011 3.2B FY2021 FY2022 revenue 3.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000943819-24-000013 FY2022 net income 779.4M · NetIncomeLoss, 0000943819-24-000013 3.6B FY2022 FY2023 revenue 4.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000943819-25-000035 FY2023 net income 897.6M · NetIncomeLoss, 0000943819-25-000035 4.2B FY2023 FY2024 revenue 4.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000943819-26-000047 FY2024 net income 1.0B · NetIncomeLoss, 0000943819-26-000047 4.7B FY2024 FY2025 revenue 5.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000943819-26-000047 FY2025 net income 1.4B · NetIncomeLoss, 0000943819-26-000047 5.1B FY2025 FY2026 revenue 5.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000943819-26-000047 FY2026 net income 1.5B · NetIncomeLoss, 0000943819-26-000047 5.7B FY2026

From XBRL in each 10-K. Hover a bar for the line item and filing. Full financials →

Statements

Income statement, balance sheet and cash flow

XBRL, each 10-K and 10-Q

RMD's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Annual Quarterly
Revenue5.7B
FY2017: 2.1BFY2018: 2.3BFY2019: 2.6BFY2020: 3.0BFY2021: 3.2BFY2022: 3.6BFY2023: 4.2BFY2024: 4.7BFY2025: 5.1BFY2026: 5.7B FY2018FY2020FY2022FY2024FY2026
Net income1.5B
FY2017: 342.3MFY2018: 315.6MFY2019: 404.6MFY2020: 621.7MFY2021: 474.5MFY2022: 779.4MFY2023: 897.6MFY2024: 1.0BFY2025: 1.4BFY2026: 1.5B FY2018FY2020FY2022FY2024FY2026
Free cash flow1.6B
FY2017: 351.8MFY2018: 442.4MFY2019: 390.3MFY2020: 706.9MFY2021: 634.0MFY2022: 216.3MFY2023: 573.6MFY2024: 1.3BFY2025: 1.7BFY2026: 1.6B FY2018FY2020FY2022FY2024FY2026
EPS (diluted)10.43
FY2017: 2.40FY2018: 2.19FY2019: 2.80FY2020: 4.27FY2021: 3.24FY2022: 5.30FY2023: 6.09FY2024: 6.92FY2025: 9.51FY2026: 10.43 FY2018FY2020FY2022FY2024FY2026
Dividend per share2.40
FY2017: 1.32FY2018: 1.40FY2019: 1.48FY2020: 1.56FY2021: 1.56FY2022: 1.68FY2023: 1.76FY2024: 1.92FY2025: 2.12FY2026: 2.40 FY2018FY2020FY2022FY2024FY2026
Diluted shares146.1M
FY2017: 142.5MFY2018: 144.0MFY2019: 144.5MFY2020: 145.7MFY2021: 146.5MFY2022: 147.0MFY2023: 147.5MFY2024: 147.6MFY2025: 147.3MFY2026: 146.1M FY2018FY2020FY2022FY2024FY2026

Revenue by business segment

year to Jun 30, 2026
RevenueSharevs year before
Sleep and Breathing Health 5.0B88.0% +10.5%
Residential Care Software 675.8M12.0% +5.4%

10-K 0000943819-26-000047, segment and revenue notes (XBRL).

Revenue by product or service

year to Jun 30, 2026
RevenueSharevs year before
Sleep and Breathing Health 5.0B88.0% +10.5%
Residential Care Software 675.8M12.0% +5.4%

10-K 0000943819-26-000047, segment and revenue notes (XBRL).

Revenue by region

year to Jun 30, 2026
RevenueSharevs year before
United States 3.6B63.0% +8.4%
Rest of the World 2.1B37.0% +12.4%

10-K 0000943819-26-000047, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue2.1B2.3B2.6B3.0B3.2B3.6B4.2B4.7B5.1B5.7B
Cost of revenue865.0M1.0B1.1B1.2B1.4B1.6B1.9B2.0B2.1B2.2B
Gross profit1.2B1.3B1.5B1.7B1.8B2.0B2.4B2.7B3.1B3.5B
R&D144.5M155.1M180.7M201.9M225.3M253.6M287.6M307.5M331.3M378.3M
SG&A554.0M600.4M645.0M676.7M670.4M737.5M874.0M917.1M993.0M1.1B
Operating income425.8M541.8M579.3M809.7M903.7M1.0B1.1B1.3B1.7B1.9B
Interest expense28.2M28.4M36.2M40.4M24.0M22.3M47.4M45.7M28.4M27.1M
Pretax income418.7M521.3M518.8M733.1M883.7M960.5M1.1B1.3B1.7B1.9B
Income tax76.5M205.7M114.3M111.4M409.2M181.0M204.1M243.8M276.8M396.1M
Net income342.3M315.6M404.6M621.7M474.5M779.4M897.6M1.0B1.4B1.5B
EPS (diluted)2.402.192.804.273.245.306.096.929.5110.43
Diluted shares142.5M144.0M144.5M145.7M146.5M147.0M147.5M147.6M147.3M146.1M
Depreciation & amortization112.2M120.0M150.8M154.8M156.8M159.6M165.2M176.9M198.5M201.3M
EBITDA538.0M661.8M730.1M964.5M1.1B1.2B1.3B1.5B1.9B2.1B
Gross margin58.1%57.0%57.3%58.1%57.5%56.6%55.8%56.7%59.4%61.1%
Operating margin20.6%23.2%22.2%27.4%28.3%28.0%26.8%28.2%32.7%33.4%
Net margin16.6%13.5%15.5%21.0%14.8%21.8%21.3%21.8%27.2%26.9%
Revenue growth-+13.2%+11.4%+13.4%+8.1%+11.9%+18.0%+10.9%+9.8%+9.9%
EPS growth--8.8%+27.9%+52.5%-24.1%+63.6%+14.9%+13.6%+37.4%+9.7%

Balance sheet

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Cash821.9M188.7M147.1M463.2M295.3M273.7M227.9M238.4M1.2B1.5B
Receivables450.5M483.7M528.5M474.6M614.3M576.0M704.9M837.3M939.5M1.0B
Inventory268.3M268.7M349.6M416.9M457.0M743.9M998.0M822.2M927.7M945.8M
Current assets1.6B1.1B1.1B1.5B1.6B1.9B2.4B2.4B3.5B4.3B
Property & equipment394.2M386.6M387.5M417.3M463.5M498.2M537.9M548.0M550.8M581.8M
Goodwill1.1B1.1B1.9B1.9B1.9B1.9B2.8B2.8B3.0B2.9B
Total assets3.5B3.1B4.1B4.6B4.7B5.1B6.8B6.9B8.2B9.0B
Accounts payable92.8M92.7M115.7M135.8M138.0M159.2M150.8M237.7M278.2M308.9M
Current liabilities360.1M511.2M556.0M602.8M911.8M689.3M758.5M910.7M1.0B1.4B
Total debt1.1B281.5M1.3B1.2B655.4M775.2M1.4B707.2M668.3M659.4M
Total liabilities1.5B1.0B2.0B2.1B1.8B1.7B2.6B2.0B2.2B2.4B
Shareholders' equity2.0B2.1B2.1B2.5B2.9B3.4B4.1B4.9B6.0B6.6B
Retained earnings2.3B2.4B2.4B2.8B3.1B3.6B4.3B5.0B6.1B7.3B

Cash flow

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating cash flow414.1M505.0M459.1M802.3M736.7M351.1M693.3M1.4B1.8B1.8B
Capital spending62.2M62.6M68.7M95.3M102.7M134.8M119.7M99.5M89.9M156.3M
Free cash flow351.8M442.4M390.3M706.9M634.0M216.3M573.6M1.3B1.7B1.6B
Stock-based pay (added back)45.9M48.4M52.1M57.6M63.9M65.3M71.1M80.2M91.7M104.3M
Dividends paid186.3M199.5M211.7M225.1M226.7M245.3M258.3M282.3M310.9M349.7M
Buybacks-53.8M22.8M--00150.0M300.0M700.0M
Acquisitions7.3M902K951.4M27.9M39.1M42.8M1.0B133.5M139.2M350.7M
Debt raised450.0M350.0M1.5B1.2B90.0M288.0M1.1B105.0M00
Debt repaid545.0M1.1B711.7M1.3B612.0M166.0M405.0M835.0M40.0M10.0M
Investing cash flow-81.9M-101.8M-1.1B-179.9M-158.5M-229.9M-1.2B-269.8M-200.0M-545.2M
Financing cash flow-262.9M-1.0B580.6M-317.3M-764.6M-128.4M422.9M-1.1B-606.3M-1.0B
Dividend per share1.321.401.481.561.561.681.761.922.122.40

Stock-based pay and leases

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Stock-based pay (expense)45.9M48.4M52.1M57.6M63.9M65.3M71.1M80.2M91.7M104.3M
Stock-based pay / revenue2.2%2.1%2.0%1.9%2.0%1.8%1.7%1.7%1.8%1.8%
Operating lease cost---26.5M35.5M35.3M33.6M41.0M39.0M45.0M
Operating lease cash paid---24.1M27.7M26.5M29.0M30.6M35.7M41.3M
Right-of-use assets---118.3M128.6M132.3M128.0M151.1M167.5M153.2M
Operating lease liabilities---123.1M138.4M142.3M138.8M166.7M183.5M166.6M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Next Peers in numbers →